This story has been updated to reflect the sensitivity and specificity data for the test the Wistar Institute presented at CHEST 2016. 

NEW YORK (GenomeWeb) – As a gene expression classifier test for lung nodules heads toward the clinic, the organizations developing the test — the Wistar Institute and OncoCyte — are revealing more about the path they've taken and what it took to get where they are.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.